#USA #Texas #Canopy #Texas Oncology #Continuous Care

Canopy and Texas Oncology: A Transformative Partnership

In an important development within the oncology world, Canopy, known as the first Continuous Care Platform designed specifically for cancer treatment, has established a multi-year partnership with Texas Oncology. This collaboration aims to improve patient outcomes by implementing advanced technologies and comprehensive care strategies throughout their expansive network. Texas Oncology is recognized as one of the largest community-based oncology practices in the United States, boasting nearly 1,000 healthcare providers across 280 locations in Texas.

The agreement builds upon a successful initial pilot program launched at the Amarillo Cancer Center, where Canopy's platform demonstrated significant benefits in enhancing patient care. As Dr. R. Steven Paulson, President and CEO of Texas Oncology, notes, the rapid pace of innovation in cancer therapies requires continuous evolution in care practices. This partnership ensures Texas Oncology remains at the forefront of cancer treatment, enabling them to set new standards tailored to each patient's individual journey.

Addressing Challenges in Oncology

In today's oncology landscape, practices face multifaceted challenges, ranging from technological limitations to reimbursement hurdles. Debra Patt, MD, PhD, MBA, who serves as Executive Vice President of Public Policy and Strategy for Texas Oncology, emphasizes the critical need to expand care beyond just the clinic setting. The collaboration with Canopy is anticipated to alleviate some of these challenges by improving clinical outcomes and operational efficiencies.

Utilizing Canopy's automation and clinical decision-support tools, Texas Oncology aims to refine care delivery, reducing the administrative burden on their teams. The platform facilitates proactive engagement with patients, helping healthcare providers address issues and capture necessary reimbursements through various programs designed for remote patient monitoring and chronic care management.

Proving Improved Patient Outcomes

Canopy's innovative approach has already garnered impressive results in real-world settings. Presentations at significant medical conferences, namely the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH), highlight the platform's effectiveness:

• - 45% improvement in treatment persistence after three months,
• - 22% reduction in emergency room visits and hospitalizations per 100 patient months,
• - 88% sustained patient engagement at the six-month mark.

Most recently, Canopy's data showcased a 37% reduction in treatment discontinuation at three months and improved early toxicity detection with bispecific antibody therapies. This data reinforces the necessity of integrated platforms like Canopy in enhancing patient support and delivering more effective oncological care.

Seamless Integration for Enhanced Care

A remarkable aspect of the partnership is the integration of Canopy's system with iKnowMed, Ontada's award-winning electronic health record (EHR) system. This partnership, part of McKesson’s suite of oncology solutions, ensures a unified experience that allows care teams to utilize a single ecosystem efficiently without the traditional quilting of disparate systems.

Lavi Kwiatkowsky, CEO and Founder of Canopy, commented on this partnership as a crucial step in their mission to standardize continuous care for all cancer patients. He praised Texas Oncology's commitment to innovation and dedication to improving patient care. Together, they aim to establish a new benchmark for AI-powered, continuous oncology care.

About the Partners

Canopy

Canopy focuses on enhancing the oncology treatment process by providing a comprehensive platform to monitor patient care between clinic visits. Their multi-channel ePRO and remote triage systems allow practices to identify and assist patients effectively while also tapping into new reimbursement opportunities.

Texas Oncology

As an independent practice with over 530 physicians, Texas Oncology provides extensive, multidisciplinary cancer care. They cater to more than 71,000 new cancer patients annually and have played a significant role in the development of numerous FDA-approved therapies through community-based clinical trials.

Conclusion

The partnership between Canopy and Texas Oncology stands as a pivotal development in advancing cancer care. By harnessing the powers of innovative technology and comprehensive patient support, they are set to redefine how oncology practices can deliver enhanced care tailored to individual patient needs. As the future unfolds, the continued evolution of such collaborations will be crucial in improving the health outcomes for those battling cancer.